Abbott announced that it has received CE Mark for its next-generation XIENCE PRIME Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease.
XIENCE PRIME leverages and will build upon the outstanding body of clinical evidence from the SPIRIT family of clinical trials. The modified design features of the stent and delivery system are intended to make it easier for physicians to deliver the stent to the treatment area, said Robert Hance, senior vice president, vascular, Abbott. As part of Abbott’s leadership in drug eluting stents, we are committed to advancing treatment options and look forward to making the innovative XIENCE PRIME stent available to physicians and patients in Europe in the upcoming months.
XIENCE PRIME utilizes the same well-studied drug and proven biocompatible polymer as Abbott’s market-leading XIENCE V Everolimus Eluting Coronary Stent System. In addition, it offers a novel stent design and a modified delivery system designed for greater flexibility and improved deliverability. XIENCE PRIME uses cobalt chromium technology, which allows for very thin struts while maintaining strength to support the vessel as well as excellent visibility under X-ray during the stent implantation procedure. XIENCE PRIME is based upon the proven design of the MULTI-LINK family of stents, which is the most widely used stent platform in the world – more than 2 million of Abbott’s cobalt chromium stents have been implanted worldwide.